Recombinant Human Anti-CD19 x Human Anti-CD47 Bispecific Antibody (scIgG) (SCIGG-H219)

Recombinant Anti-CD19 x Anti-CD47 Bispecific Antibody (scIgG) is designed to be expressed as two chains, each chain has the same units with their parental IgG antibodies, anti-CD19 and anti-CD47 IgGs. The two chains form heterodimer via Fc KIH technology. This BsAb can retarget macrophages to tumor cells. It is designed for the research of B cell lymphoma; Follicular lymphoma; Burkitt lymphoma; Leukemia therapy.

Datasheet INQUIRY

Specifications

Targets

CD19 & CD47

Type

Single chain IgGs

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

B cell lymphoma; Follicular lymphoma; Burkitt lymphoma; Leukemia

Targets

Target 1

CD19

Gene ID

930

UniProt ID

P15391

Alternative Names

CD19; CD19 molecule; Cluster of differentiation 19; B4; CVID3; B-lymphocyte antigen CD19; differentiation antigen CD19; T-cell surface antigen Leu-12; B-lymphocyte surface antigen B4

Target 2

CD47

Gene ID

961

UniProt ID

Q08722

Alternative Names

CD47; CD47 molecule; IAP; OA3; MER6; leukocyte surface antigen CD47; CD47 glycoprotein; Rh-related antigen; integrin associated protein; integrin-associated protein; integrin-associated signal transducer; antigenic surface determinant protein OA3; antigen identified by monoclonal antibody 1D8; CD47 antigen (Rh-related antigen, integrin-associated signal transducer)

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Human Anti-CD19 x Human Anti-CD47 Bispecific Antibody (scIgG) (SCIGG-H219). Click the button below to contact us or submit your feedback about this product.

Recombinant Human Anti-CD19 x Human Anti-CD47 Bispecific Antibody (scIgG) (CAT#: SCIGG-H219)

Specifications

Targets

Customer Reviews and Q&As